Plasma 25-hydroxyVitamin D, Vitamin D binding protein, and risk of colorectal cancer in the nurses' health study

Cancer Prevention Research

Volumn 9, Issue 8, 2016, Pages 664-672

  Song, Mingyang ^a,b   Konijeti, Gauree Gupta ^c,d   Yuan, Chen ^b   Ananthakrishnan, Ashwin N ^a   Ogino, Shuji ^b,e,f   Fuchs, Charles S ^e,g   Giovannucci, Edward L ^b,g   Ng, Kimmie ^e   Chan, Andrew T ^a,g,h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c SCRIPPS CLINIC   (United States)

^d SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; VITAMIN D BINDING PROTEIN; 25-HYDROXYVITAMIN D; TUMOR MARKER; VITAMIN D;

ADULT; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENETIC VARIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SECONDARY ANALYSIS; VITAMIN BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; BLOOD; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; ODDS RATIO; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; BIOMARKERS, TUMOR; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84983628558     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-16-0053     Document Type: Article

References (52)

1. Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology 2015;148:1244-60.
2. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014;14:342-57.
3. Touvier M, Chan DSM, Lau R, Aune D, Vieira R, Greenwood DC, et al.Metaanalyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011;20:1003-16
4. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006;98:451-9.
5. Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 1986;63:954-9.
6. Arnaud J, Constans J. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 1993;92:183-8.
7. Braun A, Bichlmaier R, Cleve H. Molecular analysis of the gene for the human vitamin-D-binding protein (group-specific component): allelic differences of the common genetic GC types. Hum Genet 1992;89:401-6.
8. Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, et al. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 2011;26:1609-16.
9. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006;372:33-42.
10. Weinstein SJ, Purdue MP, Smith-Warner SA, Mondul AM, Black A, Ahn J, et al. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer 2015;136:E654-64.
11. Anic GM, Weinstein SJ, Mondul AM, Mannisto S, Albanes D. Serum vitamin D, vitamin D binding protein, and risk of colorectal cancer. PLoS One 2014;9:e102966.
12. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004;13:1502-8.
13. Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, Giovannucci EL. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 2007;99:1120-9.
14. Song M, Wu K, Chan AT, Fuchs CS, Giovannucci EL. Plasma 25-hydroxyvitamin D and risk of colorectal cancer after adjusting for inflammatory markers. Cancer Epidemiol Biomarkers Prev 2014;23:2175-80.
15. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health 1997;6:49-62.
16. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, editors. AJCC cancer staging handbook. 6th ed. New York: Springer; 2002.
17. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87: 1297-302.
18. Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 2011;140:799-808, quiz e11.
19. Song M,Wu K, Ogino S, Fuchs CS, Giovannucci EL, Chan AT. A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer 2013;108:1891-8.
20. Mehta RS, Song M, BezawadaN,Wu K,Garcia-Albeniz X, Morikawa T, et al. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J Natl Cancer Inst 2014;106:dju016.
21. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013;369:1991-2000.
22. Hiraki LT, Joshi AD, Ng K, Fuchs CS, Ma J, Hazra A, et al. Joint effects of colorectal cancer susceptibility loci, circulating 25-hydroxyvitamin D and risk of colorectal cancer. PLoS One 2014;9:e92212.
23. Reid D, Toole BJ, Knox S, Talwar D, Harten J, O'Reilly DS, et al. The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. Am J Clin Nutr 2011;93:1006-11.
24. Anderson TW. Introduction to multivariate statistics. New York, NY: John Wiley and Sons; 1984.
25. Hollis BW, Bikle DD. Vitamin D-binding protein and vitamin D in blacks and whites. N Engl J Med 2014;370:879-80.
26. Deeb KK, Trump DL, Johnson CS. VitaminDsignalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007;7:684-700.
27. Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, et al. A trial of calciumand vitamin Dfor the prevention of colorectal adenomas. NEngl J Med 2015;373:1519-30.
28. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96.
29. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469.
30. Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR, et al. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). J Clin Endocrinol Metab 2012;97:614-22.
31. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-91.
32. Holick MF. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:2287-8.
33. Giovannucci E. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:2287-8.
34. Bolland MJ, Grey A, Gamble GD, Reid IR. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am J Clin Nutr 2011;94:1144-9.
35. White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab 2000;11:320-7.
36. Yamamoto N, Kumashiro R. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. J Immunol 1993;151:2794-802.
37. Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003;5:32-40.
38. Gregory KJ, Zhao B, Bielenberg DR, Dridi S,Wu J, Jiang W, et al. Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One 2010;5:e13428.
39. Kew RR, Webster RO. Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg. J Clin Invest 1988;82:364-9.
40. Perez HD, Kelly E, Chenoweth D, Elfman F. Identification of the C5a des Arg cochemotaxin. Homology with vitamin D-binding protein (groupspecific component globulin). J Clin Invest 1988;82:360-3.
41. Weintraub SJ. Vitamin D-binding protein and vitamin D in blacks and whites. N Engl J Med 2014;370:878.
42. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999;96:507-15.
43. Ternes SB, RowlingMJ. VitaminDtransport proteinsmegalin and disabled-2 are expressed in prostate and colon epithelial cells and are induced and activated by all-trans-retinoic acid. Nutr Cancer 2013;65:900-7.
44. Carter GD, Phinney KW. Assessing vitaminDstatus: time for a rethink?Clin Chem 2014;60:809-11.
45. Chun RF. New perspectives on the vitamin D binding protein. Cell Biochem Funct 2012;30:445-56.
46. Nielson CM, Jones KS, Chun RF, Jacobs J, Wang Y, Hewison M, et al. Role of assay type in determining free 25-hydroxyvitamin D levels in diverse populations. N Engl J Med 2016;374:1695-6.
47. Nielson CM, Jones KS, Chun RF, Jacobs JM, Wang Y, Hewison M, et al. Free 25-hydroxyvitamin D: impact of vitamin D binding protein assays on racial-genotypic associations. J Clin Endocrinol Metab 2016;101: 2226-34.
48. Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007;99:1594-602.
49. Haddad JG. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. J Steroid Biochem Mol Biol 1995;53:579-82.
50. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy-and 25-hydroxyvitaminDand subsequent risk of prostate cancer. Cancer Causes Control 2004;15:255-65.
51. Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2010;19:927-31.
52. Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol 2010;171:903-8.